(no title)
paviva | 3 years ago
Pyridoxine/doxylamine is nothing new, and was released in the USA in the fifties, and withdrawn from the market in the early eighties due to numerous (baseless) lawsuit alleging it caused birth defects. This formulation is known as Diclectin in Canada, where there were no lawsuits (and thus, no withdrawal), and it costs pennies.
The medication was reintroduced in the USA about 10 years ago as Diclegis by another manufacturer, and Bonjesta is essentially Dicglesis with improved pharmacokinetics (whether this matters clinically is another question).
It is interesting to note that Bonjesta is produced by Duchesnay USA, which is owned by the Canadian company Duchesnay, which markets Diclectin here in Canada. I suspect that no American company is willing to risk a lawsuit *even* at the current seemingly absurdly high pricing. Duchesnay USA is essentially a mono-pill company, and I imagine that the strategy is that they're willing to go under in case of a class action.
No comments yet.